JP2019519221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519221A5 JP2019519221A5 JP2018560974A JP2018560974A JP2019519221A5 JP 2019519221 A5 JP2019519221 A5 JP 2019519221A5 JP 2018560974 A JP2018560974 A JP 2018560974A JP 2018560974 A JP2018560974 A JP 2018560974A JP 2019519221 A5 JP2019519221 A5 JP 2019519221A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- appendix
- protein
- acid sequence
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194601A JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339182P | 2016-05-20 | 2016-05-20 | |
| US62/339,182 | 2016-05-20 | ||
| US201662421665P | 2016-11-14 | 2016-11-14 | |
| US62/421,665 | 2016-11-14 | ||
| PCT/US2017/033815 WO2017201527A2 (en) | 2016-05-20 | 2017-05-22 | Gene therapy methods for age-related diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194601A Division JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519221A JP2019519221A (ja) | 2019-07-11 |
| JP2019519221A5 true JP2019519221A5 (OSRAM) | 2020-08-27 |
| JP7632835B2 JP7632835B2 (ja) | 2025-02-19 |
Family
ID=60326179
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560974A Active JP7632835B2 (ja) | 2016-05-20 | 2017-05-22 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2021194601A Active JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A Pending JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A Pending JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194601A Active JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A Pending JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A Pending JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12281154B2 (OSRAM) |
| EP (1) | EP3458585A4 (OSRAM) |
| JP (4) | JP7632835B2 (OSRAM) |
| CN (2) | CN109844124B (OSRAM) |
| AU (2) | AU2017268469C1 (OSRAM) |
| BR (1) | BR112018073861A2 (OSRAM) |
| CA (1) | CA3025020A1 (OSRAM) |
| MX (2) | MX2018014256A (OSRAM) |
| WO (1) | WO2017201527A2 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11208443B2 (en) * | 2017-02-14 | 2021-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | NAF-1 derived peptides and uses thereof |
| MX2019011040A (es) * | 2017-03-17 | 2020-01-20 | Adverum Biotechnologies Inc | Composiciones y metodos para potenciar la expresion genica. |
| WO2018215613A1 (en) * | 2017-05-24 | 2018-11-29 | Universitat Autonoma De Barcelona | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
| CN111182915A (zh) | 2017-08-15 | 2020-05-19 | 金德雷德生物科学股份有限公司 | 兽药用IgG Fc变体 |
| CN111491657A (zh) * | 2017-10-20 | 2020-08-04 | 哈佛学院院长及董事 | 用于异源蛋白质生产的人工分泌肽 |
| US11807850B2 (en) | 2017-12-06 | 2023-11-07 | Klogenix Llc | Compositions and methods for modulating gene expression |
| KR20210052469A (ko) * | 2018-08-30 | 2021-05-10 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 갈락토스혈증의 치료를 위한 유전자 요법 |
| US20210388053A1 (en) * | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| US12134772B2 (en) | 2018-11-21 | 2024-11-05 | Advantage Therapeutics, Inc. | Increasing gene expression |
| BR112021010038A2 (pt) * | 2018-11-26 | 2021-08-24 | Universitat Autonoma De Barcelona | Terapia gênica com fator de crescimento de fibroblastos 21 (fgf21) |
| AU2020279829A1 (en) | 2019-05-23 | 2021-12-02 | Christiana Care Gene Editing Institute, Inc. | Gene knockout of NRF2 for treatment of cancer |
| EP3973056A1 (en) | 2019-05-23 | 2022-03-30 | Christiana Care Health Services, Inc. | Gene knockout of variant nrf2 for treatment of cancer |
| AR119271A1 (es) | 2019-06-11 | 2021-12-09 | Shire Human Genetic Therapies | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada |
| US10653731B1 (en) * | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| KR102281858B1 (ko) * | 2019-09-11 | 2021-07-26 | 주식회사 쎌바이오텍 | 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물 |
| EP4028532A1 (en) * | 2019-09-13 | 2022-07-20 | Rutgers, the State University of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| CN110894508B (zh) * | 2019-10-31 | 2021-08-06 | 内蒙古大学 | 一种调控白色脂肪棕色化的基因Adra1a的应用 |
| EP4069313A4 (en) * | 2019-12-05 | 2024-02-28 | President And Fellows Of Harvard College | METHODS OF TREATMENT OF OSTEOARTHRITIS |
| JP7588466B2 (ja) * | 2020-01-22 | 2024-11-22 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| JP2023524010A (ja) * | 2020-04-28 | 2023-06-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 高効率遺伝子送達系 |
| EP4149503A1 (en) * | 2020-05-13 | 2023-03-22 | Lysogene | Compositions and methods for treating gm1 gangliosidosis and other disorders |
| MX2022014754A (es) * | 2020-05-26 | 2023-01-16 | UNIV AUTòNOMA DE BARCELONA | Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central. |
| CN114181944B (zh) * | 2020-09-14 | 2023-10-03 | 中国科学院动物研究所 | 突变基因及构建短肢性侏儒症小型猪模型的方法和用途 |
| WO2022115739A2 (en) * | 2020-11-30 | 2022-06-02 | Cellular Longevity, Inc. | Lnp and liposome compositions for longevity in mammals and methods of using the same |
| WO2022130014A1 (en) | 2020-12-16 | 2022-06-23 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| KR102590276B1 (ko) * | 2021-01-04 | 2023-10-16 | 부산대학교 산학협력단 | 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도 |
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| CN113088531B (zh) * | 2021-03-25 | 2023-10-17 | 四川省药品检验研究院(四川省医疗器械检测中心) | 牛源性成分定量分析标准质粒、制备及检测方法及应用 |
| US20240124541A1 (en) * | 2021-04-12 | 2024-04-18 | University of Florida Research Foundation, Incorprated | Compositions and methods for treating obesity |
| JP2022169389A (ja) * | 2021-04-27 | 2022-11-09 | 国立大学法人北海道大学 | イヌＴＧＦ－β受容体ＩＩ |
| US20220401583A1 (en) * | 2021-06-16 | 2022-12-22 | BioViva USA, Inc. | Treatment of age-related cognitive decline using genetically modified viral vectors |
| US20230018934A1 (en) * | 2021-07-16 | 2023-01-19 | Genflow Biosciences Srl | Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus |
| WO2023053123A1 (en) * | 2021-09-29 | 2023-04-06 | Sirt 6 Research And Development (2020) Ltd | A method for treating a disease |
| CN114921480A (zh) * | 2022-06-09 | 2022-08-19 | 国科宁波生命与健康产业研究院 | 一种骨细胞Terc基因敲除小鼠模型的构建方法 |
| JP2025531584A (ja) * | 2022-09-21 | 2025-09-19 | レジュヴェネイト バイオ インコーポレイテッド | 僧帽弁疾患を治療するための遺伝子治療方法 |
| WO2024064785A2 (en) * | 2022-09-21 | 2024-03-28 | Rejuvenate Bio | Gene therapy methods for familial partial lipodystrophy |
| WO2024064796A2 (en) * | 2022-09-21 | 2024-03-28 | Rejuvenate Bio | Gene therapy methods for arrhythmogenic cardiomyopathy |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
| EP4566618A1 (en) * | 2023-12-06 | 2025-06-11 | ADvantage Therapeutics, Inc. | Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight |
| WO2025109173A1 (en) | 2023-11-22 | 2025-05-30 | Advantage Therapeutics, Inc. | Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| KR20010006534A (ko) | 1997-04-18 | 2001-01-26 | 아스트루 마이클 제이 | Ⅱ형 ｔｇｆ-베타 수용체／면역글로불린 불변 영역 융합 단백질 |
| US7622300B2 (en) * | 1998-06-03 | 2009-11-24 | Kappes John C | Trans-lentiviral vector particles and transduction of eukaryotic cells therewith |
| US7419829B2 (en) * | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| AU2003209226A1 (en) * | 2002-01-11 | 2003-07-30 | Michael Tennant | Adiponectin gene therapy |
| US8158589B2 (en) * | 2003-08-22 | 2012-04-17 | Proyecto Biomedicine Cima, S.L. | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
| US7511056B2 (en) * | 2004-11-10 | 2009-03-31 | Eli Lilly And Company | TGF-β inhibitors |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| EA016038B1 (ru) * | 2005-04-22 | 2012-01-30 | Эли Лилли Энд Компани | Антитело к tgf-бета и его применение |
| DE102005061840A1 (de) * | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
| US20070292922A1 (en) | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| NZ575804A (en) * | 2006-09-13 | 2012-01-12 | Univ Columbia | Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| JP2010529859A (ja) * | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質 |
| US8236557B2 (en) * | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| IL323000A (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| AR083445A1 (es) * | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| ES2423798T3 (es) * | 2010-11-19 | 2013-09-24 | Universitätsklinikum Freiburg | Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados |
| EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| MX2014002260A (es) * | 2011-08-31 | 2014-08-18 | Amgen Inc | Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1. |
| US9006400B2 (en) * | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
| TWI614031B (zh) * | 2011-11-03 | 2018-02-11 | 國立陽明大學 | 防止皮膚老化相關症狀的醫藥組合物及其使用方法 |
| US9422561B2 (en) | 2012-01-24 | 2016-08-23 | Bar-Ilan University | Treatment of disease by modulation of SIRT6 |
| CN103665166A (zh) * | 2012-09-03 | 2014-03-26 | 福又达生物科技股份有限公司 | 犬融合干扰素 |
| WO2014152993A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Regents Of The University Of Oklahoma | Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions |
| CA2945325A1 (en) * | 2014-04-08 | 2015-10-15 | University Of Southern California | Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing |
| KR20150135148A (ko) * | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| CN107108710B (zh) * | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| EP3334750B1 (en) * | 2015-08-11 | 2022-10-05 | Anie Philip | Peptidic tgf-beta antagonists |
-
2017
- 2017-05-22 CA CA3025020A patent/CA3025020A1/en active Pending
- 2017-05-22 CN CN201780058862.1A patent/CN109844124B/zh active Active
- 2017-05-22 JP JP2018560974A patent/JP7632835B2/ja active Active
- 2017-05-22 MX MX2018014256A patent/MX2018014256A/es unknown
- 2017-05-22 AU AU2017268469A patent/AU2017268469C1/en active Active
- 2017-05-22 EP EP17800329.9A patent/EP3458585A4/en active Pending
- 2017-05-22 US US16/302,865 patent/US12281154B2/en active Active
- 2017-05-22 BR BR112018073861-1A patent/BR112018073861A2/pt unknown
- 2017-05-22 CN CN202311189446.9A patent/CN117535350A/zh active Pending
- 2017-05-22 WO PCT/US2017/033815 patent/WO2017201527A2/en not_active Ceased
-
2018
- 2018-11-20 MX MX2022000085A patent/MX2022000085A/es unknown
-
2021
- 2021-11-30 JP JP2021194601A patent/JP7315284B2/ja active Active
-
2023
- 2023-03-20 JP JP2023044658A patent/JP2023078338A/ja active Pending
-
2024
- 2024-09-23 AU AU2024219991A patent/AU2024219991A1/en active Pending
- 2024-11-11 US US18/942,898 patent/US20250122267A1/en active Pending
-
2025
- 2025-02-25 JP JP2025028446A patent/JP2025078652A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519221A5 (OSRAM) | ||
| US7351577B2 (en) | Adeno-associated vector compositions for expression of Factor VIII | |
| Skopenkova et al. | Muscle-specific promoters for gene therapy | |
| JP2022033855A (ja) | 加齢関連疾患及び症状の遺伝子治療法 | |
| JP2022033855A5 (OSRAM) | ||
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP7659550B2 (ja) | アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療 | |
| JP2002527493A (ja) | 標的細胞による第ｖｉｉｉ因子の発現のためのアデノ随伴ベクター | |
| CN113316639A (zh) | 用于治疗庞贝氏病的治疗性腺相关病毒 | |
| US6967018B2 (en) | Adiponectin gene therapy | |
| JP2012521750A (ja) | 肝硬変及び肝線維症の治療のための方法及び組成物 | |
| JP2022512689A (ja) | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 | |
| JP2022527597A (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| CN113692411A (zh) | 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗 | |
| JP2021532810A (ja) | 糖原病ｉｉｉの処置のためのミニｇｄｅ | |
| JP2023076698A (ja) | ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法 | |
| JP2025535114A (ja) | 中枢神経系における遺伝子発現のための核酸調節エレメント及び使用方法 | |
| JP2018526994A (ja) | ペット治療用ａａｖ−ｅｐｏ | |
| TWI883088B (zh) | 用於治療韓特氏病之腺相關病毒載體 | |
| JP2002534077A (ja) | トランスジェニック動物における分泌型ヒトアルファ−フェト蛋白質の発現 | |
| KR20230112672A (ko) | 신경변성 질환을 위한 유전자 요법 | |
| US20250327080A1 (en) | Rnas targeting activin a subunits | |
| CN120665952A (zh) | 一种修复肌萎缩侧索硬化致病突变基因的编辑系统 | |
| WO2025201333A1 (zh) | 递送Otof基因的双载体系统和其用途 | |
| WO2024097521A2 (en) | Compositions for treatment of osteogenesis imperfecta |